Background The current COVID‐19 pandemic, caused by SARS‐CoV‐2, has emerged as a
public health emergency. All nations are seriously challenged as the virus spreads rapidly …

Background Inflammatory bowel disease (IBD) is a chronic relapsing-remitting disease. An
adverse immune reaction toward the intestinal microbiota is involved in the pathophysiology …

The pharmacotherapy of inflammatory bowel diseases (Crohn's disease and ulcerative
colitis) has experienced significant progress with the advent of monoclonal antibodies …

Background Tioguanine (or thioguanine) is an alternative drug for IBD patients who fail prior
conventional immunomodulating therapy. Aim To report effectiveness, safety and …

Therapeutic drug monitoring (TDM) of tumor necrosis factor-α (TNFα)-inhibitors adalimumab
and infliximab is important to establish optimal drug dose and maximize treatment efficacy …

Background Anxiety and depression symptoms are very common in patients with
inflammatory bowel disease (IBD). We aimed to explore the impact of anxiety and …

There are limited data on therapeutic drug monitoring (TDM) in inflammatory bowel disease
(IBD) patients treated with vedolizumab (VDZ). Although an exposure–response relation has …

Inflammatory bowel disease (IBD) is a gastrointestinal disorder, affecting about several
million people worldwide. Current treatments fail to adequately control some clinical …

Biologicals introduced a major shift in the treatment of patients suffering from inflammatory
bowel diseases. Despite providing a tight disease control for many patients, a considerable …

Introduction Despite new treatment options for inflammatory bowel disease (IBD),
conventional thiopurines remain a common treatment option for maintaining remission …